Logo image of EVO

EVOTEC SE - SPON ADR (EVO) Stock Fundamental Analysis

NASDAQ:EVO - Nasdaq - US30050E1055 - ADR - Currency: USD

4.12  +0.05 (+1.23%)

Fundamental Rating

2

Taking everything into account, EVO scores 2 out of 10 in our fundamental rating. EVO was compared to 56 industry peers in the Life Sciences Tools & Services industry. EVO has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, EVO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

EVO had negative earnings in the past year.
In the past year EVO had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: EVO reported negative net income in multiple years.
Each year in the past 5 years EVO had a positive operating cash flow.
EVO Yearly Net Income VS EBIT VS OCF VS FCFEVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

EVO's Return On Assets of -10.64% is in line compared to the rest of the industry. EVO outperforms 57.14% of its industry peers.
EVO's Return On Equity of -22.69% is in line compared to the rest of the industry. EVO outperforms 50.00% of its industry peers.
Industry RankSector Rank
ROA -10.64%
ROE -22.69%
ROIC N/A
ROA(3y)-7.25%
ROA(5y)-2.34%
ROE(3y)-14.29%
ROE(5y)-5.27%
ROIC(3y)N/A
ROIC(5y)N/A
EVO Yearly ROA, ROE, ROICEVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20

1.3 Margins

The Gross Margin of EVO (13.62%) is worse than 85.71% of its industry peers.
EVO's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for EVO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 13.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.23%
GM growth 5Y-13.5%
EVO Yearly Profit, Operating, Gross MarginsEVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20

More info and screens

3

2. Health

2.1 Basic Checks

EVO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EVO has been increased compared to 1 year ago.
The number of shares outstanding for EVO has been increased compared to 5 years ago.
Compared to 1 year ago, EVO has an improved debt to assets ratio.
EVO Yearly Shares OutstandingEVO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
EVO Yearly Total Debt VS Total AssetsEVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

EVO has an Altman-Z score of 0.71. This is a bad value and indicates that EVO is not financially healthy and even has some risk of bankruptcy.
EVO has a worse Altman-Z score (0.71) than 67.86% of its industry peers.
A Debt/Equity ratio of 0.46 indicates that EVO is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.46, EVO is in line with its industry, outperforming 42.86% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF N/A
Altman-Z 0.71
ROIC/WACCN/A
WACC6.71%
EVO Yearly LT Debt VS Equity VS FCFEVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

EVO has a Current Ratio of 2.03. This indicates that EVO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.03, EVO is in line with its industry, outperforming 41.07% of the companies in the same industry.
A Quick Ratio of 1.93 indicates that EVO should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.93, EVO perfoms like the industry average, outperforming 44.64% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.03
Quick Ratio 1.93
EVO Yearly Current Assets VS Current LiabilitesEVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

EVO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -136.17%.
The Revenue has been growing slightly by 1.50% in the past year.
The Revenue has been growing by 12.29% on average over the past years. This is quite good.
EPS 1Y (TTM)-136.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.44%
Revenue 1Y (TTM)1.5%
Revenue growth 3Y8.85%
Revenue growth 5Y12.29%
Sales Q2Q%-4.19%

3.2 Future

EVO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.33% yearly.
The Revenue is expected to grow by 9.40% on average over the next years. This is quite good.
EPS Next Y74%
EPS Next 2Y37.84%
EPS Next 3Y32.3%
EPS Next 5Y18.33%
Revenue Next Year8.33%
Revenue Next 2Y9.65%
Revenue Next 3Y9.45%
Revenue Next 5Y9.4%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
EVO Yearly Revenue VS EstimatesEVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
EVO Yearly EPS VS EstimatesEVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EVO. In the last year negative earnings were reported.
Also next year EVO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EVO Price Earnings VS Forward Price EarningsEVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60 -60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, EVO is valued a bit cheaper than 60.71% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 56.11
EVO Per share dataEVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

EVO's earnings are expected to grow with 32.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.84%
EPS Next 3Y32.3%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EVO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVOTEC SE - SPON ADR

NASDAQ:EVO (7/14/2025, 1:59:33 PM)

4.12

+0.05 (+1.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)04-17 2025-04-17/bmo
Earnings (Next)08-13 2025-08-13/bmo
Inst Owners57.36%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner Change0%
Market Cap1.46B
Analysts76.67
Price Target6.02 (46.12%)
Short Float %0.25%
Short Ratio5.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.02%
Min Revenue beat(2)-5.1%
Max Revenue beat(2)-0.93%
Revenue beat(4)0
Avg Revenue beat(4)-4.55%
Min Revenue beat(4)-6.12%
Max Revenue beat(4)-0.93%
Revenue beat(8)2
Avg Revenue beat(8)-1.47%
Revenue beat(12)5
Avg Revenue beat(12)2.41%
Revenue beat(16)9
Avg Revenue beat(16)4.66%
PT rev (1m)0.61%
PT rev (3m)-13.62%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-77.96%
EPS NY rev (1m)0%
EPS NY rev (3m)-8.98%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.05%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.86%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.59
P/FCF N/A
P/OCF 36.2
P/B 1.37
P/tB 2.07
EV/EBITDA 56.11
EPS(TTM)-0.65
EYN/A
EPS(NY)-0.06
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)0.11
OCFY2.76%
SpS2.59
BVpS3
TBVpS1.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.64%
ROE -22.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 13.62%
FCFM N/A
ROA(3y)-7.25%
ROA(5y)-2.34%
ROE(3y)-14.29%
ROE(5y)-5.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.23%
GM growth 5Y-13.5%
F-Score4
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF N/A
Debt/EBITDA 18.85
Cap/Depr 113.07%
Cap/Sales 14.58%
Interest Coverage N/A
Cash Conversion 156.03%
Profit Quality N/A
Current Ratio 2.03
Quick Ratio 1.93
Altman-Z 0.71
F-Score4
WACC6.71%
ROIC/WACCN/A
Cap/Depr(3y)186.39%
Cap/Depr(5y)182.37%
Cap/Sales(3y)22.79%
Cap/Sales(5y)21.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-136.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.44%
EPS Next Y74%
EPS Next 2Y37.84%
EPS Next 3Y32.3%
EPS Next 5Y18.33%
Revenue 1Y (TTM)1.5%
Revenue growth 3Y8.85%
Revenue growth 5Y12.29%
Sales Q2Q%-4.19%
Revenue Next Year8.33%
Revenue Next 2Y9.65%
Revenue Next 3Y9.45%
Revenue Next 5Y9.4%
EBIT growth 1Y-3.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year147.54%
EBIT Next 3Y53.1%
EBIT Next 5Y35.28%
FCF growth 1Y36.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50%
OCF growth 3Y-46.98%
OCF growth 5Y-15.47%